The cancer tissue page shows antibody staining in 20 different cancers. The assay and annotation is described
This page starts with information about the protein evidence and, when applicable, also protein class.
Below the summary, a selection of four standard cancer tissue samples is displayed as representative of the overall staining pattern.
From left: colorectal cancer, breast cancer, prostate cancer and lung cancer.
An additional 5th image can be added as a complement.
The cancer tissue summary page shows antibody staining in 20 different cancers.
The assay and annotation is described here.
For each cancer, the fraction of samples with antibody staining/protein expression level high, medium, low, or not detected are provided by the blue-scale color-coding
(as described by the color-coding scale in the box to the right).
The length of the bar represents the number of patient samples analyzed (max=12 patients).
The images and annotations can be accessed by clicking on the cancer name or protein expression bar. If more than one antibody is analyzed, the tabs at the top of the staining summary section can be used to toggle
between the different antibodies. The tooltip function displays additional data for the features in the staining summary view.
Next to the cancer staining data, the protein expression data of normal tissues or specific cell types
corresponding to each cancer are shown and protein expression levels are indicated by the blue-scale color coding.
At the bottom of the page, a summary of the overall protein expression pattern across the analyzed cancer
tissues as well as information about literature conformity are presented.
Malignancies generally displayed weak to moderate cytoplasmic immunoreactivity. Strong positivity was observed in testis cancers, carcinoids and malignant melanomas. Most renal cancers and hepatocellular carcinomas were negative. One cholangiocarcinoma showed dot-like staining pattern.
Level of antibody staining/expression
High Medium Low Not detected
The Human Protein Atlas project is funded
by the Knut & Alice Wallenberg foundation.